These once high-flying stocks no longer seem to have promising prospects.Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.Take Teladoc Health (TDOC 2.10%) and Sarepta Therapeutics (SRPT 0.65%). These two healthcare companies have lagged the market this year, but even at their current levels, they don't look particularly attractive. Here's why investors should stay away from the ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, due to alleged misleading statements and failure to disclose critical information regarding the company's competitive position and customer acquisition costs [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that LifeMD's defendants made materially false and misleading statements about the company's competitive position and financial guidance, particularly regarding customer acquisition costs in the RexMD segment and the sale of obesity treatment drugs [5]. - Investors who purchased LifeMD securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 27, 2025, to represent other class members in the litigation [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated LifeMD's competitive position; (2) Defendants ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against LifeMD, Inc. following disappointing Q2 2025 financial results and a reduced outlook, which was raised just three months prior [1][5]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for October 27, 2025 [3]. - The litigation focuses on LifeMD's statements made on May 6, 2025, when the company reported its Q1 2025 financial results and raised its full-year 2025 revenue and adjusted EBITDA guidance [3]. Group 2: Financial Performance and Guidance - LifeMD raised its guidance in May 2025, citing the creation of a competitive moat in virtual obesity care and strong performance from its RexMD brand [4]. - The company later reported Q2 2025 results that missed consensus estimates, reducing revenue guidance by approximately 6.7% to 7.3% and slashing adjusted EBITDA guidance by about 12% to 13% [5][6]. - The disappointing results were attributed to higher-than-anticipated refund rates and elevated customer acquisition costs in the competitive ED market [6]. Group 3: Investigation and Claims - Hagens Berman, a national shareholders rights firm, has opened an investigation into whether LifeMD violated securities laws [2][7]. - The investigation is focused on whether LifeMD recklessly guided on May 6, 2025, while facing challenges in its weight management and RexMD segments [7]. - The complaint alleges that LifeMD made false and misleading statements and failed to disclose crucial information while insiders sold significant amounts of their shares [4].

Core Viewpoint - Earth Science Tech, Inc. has approved a significant enhancement and a two-year extension of its common stock repurchase program, increasing total authorization to $10 million, which will now run through December 31, 2027 [1][2][3] Repurchase Program Details - The company has already deployed over $1.8 million to repurchase 20,834,214 shares since the program's inception on January 29, 2024, reflecting a commitment to enhancing shareholder value [2][4][8] - The remaining authorization for the repurchase program is $8,169,104.50, with the new expiration date set for December 31, 2027 [8] Company Overview - Earth Science Tech, Inc. operates as a strategic holding company focused on acquiring and scaling high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through its subsidiaries [5][6] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [5][7][9]

Core Points - Earth Science Tech, Inc. has announced a reduction in its authorized shares of common stock from 350 million to 300 million, reflecting the Board's confidence in the company's trajectory and commitment to long-term shareholder value [1][2][3] - The current outstanding share count is approximately 294.3 million, leading the Board to determine that the previous authorization level was unnecessary [3] Company Overview - Earth Science Tech, Inc. operates as a strategic holding company focused on acquiring and scaling high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through its subsidiaries [4] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [4][6][10] - RxCompoundStore.com is a licensed compounding pharmacy operating in multiple states and is actively pursuing licensure in the remaining U.S. states [5] - Peaks Curative is a telemedicine platform that offers consultations for compounded medications and is expanding its services nationwide [7] - Avenvi is involved in real estate development and manages the company's ongoing $5 million share repurchase program [10]

CLEARWATER, Fla., Aug. 18, 2025 /PRNewswire/ -- MedWell Ai, Inc, ("Company") (OTCQB: MWAI) is pleased to confirm the collaboration and execution of Software Development Agreement with BrighterMD, to develop and launch Company's latest initiative: TeleMD.Ai – Nationwide B2B and B2C Healthcare and Wellness Telemedicine Platform, with main focus on corporate healthcare benefits market. Scheduled to go live in October, 2025, TeleMD is designed to deliver a comprehensive telehealth primary care that is affordabl ...

Group 1 - The core viewpoint is that Hims & Hers is transitioning from being perceived merely as a telemedicine company to a comprehensive, data-driven precision health platform with software-like economics and predictable recurring revenue [1] - The company is experiencing increasing operating leverage, which indicates a potential for higher profitability as it scales [1] - The narrative surrounding Hims & Hers is often misunderstood, with the market not fully pricing in its long-term potential and scalable business model [1] Group 2 - The investment approach emphasizes a fundamental, bottom-up strategy focusing on market psychology, business durability, and valuation discipline [1] - The company is particularly appealing due to its scalable models and durable competitive advantages, which are often overlooked by investors [1] - The investment philosophy highlights the nonlinear nature of investing success, shaped by cycles and constant recalibration [1]

Core Insights - Earth Science Tech, Inc. (ETST) reported significant financial and operational developments for the first fiscal quarter ending June 30, 2025, highlighting a strategic shift towards maximizing the value of its current divisions after a period of acquisitions [1][2]. Financial Highlights - Total assets increased by 61% to $7.69 million as of June 30, 2025, compared to $4.77 million in the prior-year period [5]. - Revenue generated was $8.7 million as of June 30, 2025, up from $8.5 million in the prior-year period [5]. - The company reduced total common shares outstanding by 4.78% to 294,297,607 as of June 30, 2025, down from 309,067,711 shares in the prior-year period [5]. - Cash and cash equivalents reported at $0.88 million, a decrease from $1.38 million in the prior-year period due to capital deployment for acquisitions [5]. Strategic and Operational Updates - ETST executed its growth strategy by acquiring 100% of Las Villas Health Care, Inc. and DOConsultation, LLC, enhancing its healthcare offerings [5]. - The company secured 80% ownership of Magnefuse, LLC, and Alicat, LLC, expanding its direct-to-consumer brand portfolio [5]. - A new customer service center was established in Doral, FL, to centralize support operations across all divisions [5]. - The company joined the OTCID Tier on the OTC Markets, improving disclosure and transparency for investors [5]. - Mister Meds, LLC is now fully operational and actively dispensing in Texas, while Avenvi, LLC has commenced its first residential development project [5].

Core Insights - American Well Corporation (AMWL) reported revenue of $70.9 million for the quarter ended June 2025, reflecting a year-over-year increase of 12.9% and surpassing the Zacks Consensus Estimate by 11.42% [1] - The company's EPS was -$1.24, an improvement from -$3.36 in the same quarter last year, with a surprise of 32.61% compared to the consensus estimate of -$1.84 [1] Revenue Breakdown - Platform subscription revenue reached $40.46 million, exceeding the average estimate of $34.05 million by two analysts, marking a year-over-year increase of 47.1% [4] - Other revenue amounted to $7.69 million, surpassing the average estimate of $5.7 million, with a year-over-year change of 17.2% [4] - Revenue from visits was $22.75 million, slightly above the estimated $21.68 million, but represented a decline of 20.8% compared to the previous year [4] Stock Performance - Over the past month, shares of American Well have declined by 13.7%, contrasting with a 1% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]